<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864145</url>
  </required_header>
  <id_info>
    <org_study_id>NFH20210325</org_study_id>
    <nct_id>NCT04864145</nct_id>
  </id_info>
  <brief_title>Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation</brief_title>
  <acronym>SEASON-AR</acronym>
  <official_title>Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation: a Prospective, Multicenter, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, randomized trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe native aortic valve regurgitation (AR) who have symptoms, impaired LVEF&#xD;
      (≤55%) or left ventricular enlargement have the indications for surgery. According to data&#xD;
      from the Euro Heart Survey, only 21.8% with LVEF 30-50% and 2.7% with LVEF &lt;30% were referred&#xD;
      for surgical aortic valve replacement (SAVR) among patients with severe native aortic&#xD;
      regurgitation. Advanced age and comorbidities were often considered as main reasons to refuse&#xD;
      SAVR. The annual mortality of untreated patients with severe AR is 10-20%. Pure native AR is&#xD;
      always an exclusion criterion in all randomized controlled trials on transcatheter aortic&#xD;
      valve implantation (TAVR) because the specific anatomical features can preclude adequate&#xD;
      valve implantation. Several small, retrospective studies showed that off-label use of TAVR&#xD;
      appears to be a feasible treatment choice for AR patients at high risk for SAVR. The present&#xD;
      study aims to investigate the use of TAVR in AR patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2031</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical worsening</measure>
    <time_frame>12 months</time_frame>
    <description>A composite of all cause death, disabling stroke, or heart failure rehospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural complications</measure>
    <time_frame>12 months</time_frame>
    <description>Any aortic dissection, annular rupture, coronary artery occlusion, vascular complications, permanent pacemaker implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>12 months</time_frame>
    <description>This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class</measure>
    <time_frame>12 months</time_frame>
    <description>Classification of function capacity of the NYHA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause, cardiovascular, and non-cardiovascular mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Complications</measure>
    <time_frame>12 months</time_frame>
    <description>The original VARC definitions with BARC classifications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothetic valve dysfunction</measure>
    <time_frame>12 months</time_frame>
    <description>Any prothetic aortic valve stenosis, prothesis-patient mismatch, prosthetic aortic valve regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in medical therapy will receive conservative care, mainly including angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in TAVR group will receive transcatheter aortic valve replacement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation</intervention_name>
    <description>The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.</description>
    <arm_group_label>Transcatheter Aortic Valve Implantation</arm_group_label>
    <other_name>The VitaFlow™ system (MicroPort®, Shanghai, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical therapy</intervention_name>
    <description>Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.</description>
    <arm_group_label>Medical therapy</arm_group_label>
    <other_name>Optimal medical therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Procedural indications: symptomatic severe aortic regurgitation; no symptom plus left&#xD;
             ventricular ejection fraction ≤ 55% or left ventricular end-diastolic dimension&#xD;
             (LVEDD) &gt; 65mm or left ventricular end-systolic dimension (LVESD) &gt; 50mm;&#xD;
&#xD;
          2. Severe aortic valve regurgitation, and mean pressure gradient &lt; 20mmHg; Annular&#xD;
             perimeter ≤ 85 mm;&#xD;
&#xD;
          3. The ratio of the perimeter of the left ventricular outflow tract 4mm to the perimeter&#xD;
             of the valve annulus is 0.95-1.05;&#xD;
&#xD;
          4. STS score ≥8 or moderate to severe frailty or refused surgical valve replacement or&#xD;
             presence of any of the following factors judged to be difficult to perform the&#xD;
             surgical valve replacement:&#xD;
&#xD;
               1. Severe aorta calcification or active ascending aorta atherosclerotic plaque&#xD;
&#xD;
               2. History of mediastinum radiotherapy&#xD;
&#xD;
               3. Past mediastinitis&#xD;
&#xD;
               4. Presence of unobstructed coronary bypass implants&#xD;
&#xD;
               5. Previous more than two cardiothoracic surgeries&#xD;
&#xD;
               6. Liver cirrhosis&#xD;
&#xD;
               7. Other surgical risk factors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 60 years old;&#xD;
&#xD;
          2. Ascending aorta diameter &gt;45mm;&#xD;
&#xD;
          3. Coronary multi-vessel disease (SYNTAX score &gt;32);&#xD;
&#xD;
          4. Life expectancy &lt;1 year;&#xD;
&#xD;
          5. Left ventricular ejection fraction &lt;30%;&#xD;
&#xD;
          6. Acute myocardial infarction within 30 days;&#xD;
&#xD;
          7. Allergies or contraindications to related drugs (aspirin, clopidogrel, warfarin, or&#xD;
             contrast agents);&#xD;
&#xD;
          8. Other situations judged by the researcher as unsuitable for participating in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-Jie Zhang, MD, PhD</last_name>
    <phone>+86-25-52271350</phone>
    <email>jameszll@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Kan, MPH</last_name>
    <phone>+86-25-52271398</phone>
    <email>kanjingok@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>+86 13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shaoliang Chen</investigator_full_name>
    <investigator_title>Director of Cardiology and Cath Lab, Vice President of Nanjing First Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

